Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Acute Coronary Syndrome (ACS)Reactive HyperemiaEndothelial Dysfunction
Interventions
DRUG

Atherolive 500mg/day

"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 250 mg (one capsule ) twice daily ( total500mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."

DRUG

Atherolive 1000/day

"Patients will receive a study drug (olive leaf extracts) which will be prescribed at dose of 500 mg (two capsule ) twice daily ( total 1000mg daily) for one month.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."

DRUG

Placbo_Atherolive

"Patients will receive placebo which will be prescribed one capsule twice daily for one months.~patients will be assigned to one of three arm using a computer-generated randomization list ( 1:1:1 allocation )."

All Listed Sponsors
lead

University of Monastir

OTHER

NCT06723002 - Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter